Pharma Pulse 11/4/24: RWD Benefits in Privacy and Targeting, Challenges of Treating Type 1 Diabetes & more

Key Benefits of RWD in Privacy and Targeting Effectiveness

Ted Sweetser, VP, Ad Partnerships and Strategy, PurpleLab discussed how the use of Real-World Data has evolved in the healthcare industry in terms of privacy and targeting effectiveness.

The Challenges of Treating Type 1 Diabetes

Type 1 diabetes is a relentless disease, according to David Maahs, M.D., M.A., Ph.D., from Stanford University.

U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain Partners

Switch-overs in manufacturing, raw materials could mean higher drug prices and slower rollouts.

Top 10 Rare Diseases Pharma Company Sees 10.4% Increase in Therapy Initiation with AllazoHealth AI-Enabled Personalized Communications

AllazoHealth released a case study on a top 10 rare diseases pharma company’s use of AI-enabled personalization for communications to increase therapy initiation and decrease therapy discontinuation. The therapies had a variety of administration methods including clinic infusion, home infusion, self-injection, and oral.

Alison Guzzio on LinkedIn

Great podcast discussion between Rob Sobie & Nicholas Saraceno, editor Pharmaceutical Commerce Magazine on the impact RFID has on medication management, supply chain and ultimately, patient safety.

The full podcast can be heard here: https://hubs.ly/Q02VVHxn0

#RFID #medicationmanagement #patientsafety #DSCSAh #dataanalytics

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs